Biotage Receives its Largest Order to Date
News Aug 12, 2005
Biotage has announced that it has received its largest single order to date. It includes 31 instruments and totals approx. 15 MSEK.
The instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
"It's encouraging that we have received an order of this magnitude so soon after the acquisition of Argonaut," says Jeff Bork, president and CEO of Biotage AB.
The instruments are designed to enable the scientists to simulate a number of processes under different conditions and to move from laboratory scale to production scale. The ordered instruments will be installed at the customer's plants in the US and Europe during 2005.
"We are seeing an increased interest worldwide in the pharmaceutical industry towards tools that reduce bottlenecks for process development and full-scale production," says David Patteson, president of Biotage, Discovery Chemistry Group.
He adds, "As Medicinal Chemistry accelerates the hit-to-lead process through automation, the emphasis now moves toward getting NCEs into clinical trials."
The instruments included in the order are Advantage Series® 2410 Personal Screening Synthesizers, Advantage Series® 3400 Multi-reactor Process Chemistry Workstations and Endeavor® Parallel Catalyst-screening Instruments.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018